{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T15:30:35Z","timestamp":1769355035160,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The fixed\u2010dose combination calcipotriol (Cal; 50\u00a0\u00b5g\/g) plus betamethasone dipropionate (BD; 0.5\u00a0mg\/g) ointment and gel formulations have well\u2010established efficacy profiles in the treatment of psoriasis vulgaris (chronic plaque psoriasis); this combination has been shown to produce favourable outcomes versus either monotherapy. To improve upon the efficacy and cosmetic acceptability of these treatments Cal\/BD foam was developed, demonstrating superior efficacy in Phase II\/III studies compared with either of its monocomponents, Cal\/BD ointment, Cal\/BD gel and various other therapies for the treatment of psoriasis. Multiple outcome measures were evaluated in the clinical studies, including physician's global assessment of disease severity and modified psoriasis area and severity index. Of note, 38\u201355% of patients across studies achieved a physician's global assessment of \u2018clear\u2019 or \u2018almost clear\u2019 after 4\u00a0weeks of Cal\/BD treatment. This superior efficacy was not associated with an increased frequency or severity of adverse events, and there was no evidence for dysregulation of the hypothalamic\u2013pituitary\u2013adrenal axis or calcium homeostasis. Overall, Cal\/BD foam was efficacious, with a good tolerability profile consistent with established Cal\/BD formulations.<\/jats:p>","DOI":"10.1111\/jdv.17028","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T08:02:48Z","timestamp":1614067368000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of fixed\u2010dose combination calcipotriol\/betamethasone dipropionate foam for the treatment of psoriasis"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-1605","authenticated-orcid":false,"given":"L.","family":"Stein Gold","sequence":"first","affiliation":[{"name":"Department of Dermatology Henry Ford Hospital Detroit MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Dermatology Toulouse University and CHU Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Romiti","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital das Clinicas University of Sao Paulo Sao Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12174"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1083935"},{"key":"e_1_2_6_4_1","first-page":"34","article-title":"Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomised, double\u2010blind, multicenter, three\u2010arm, phase 2 study","volume":"9","author":"Lebwohl M","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13859"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15369"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0489-5"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17027"},{"key":"e_1_2_6_9_1","first-page":"1468","article-title":"Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris\u2013a randomised phase III study (PSO\u2010FAST)","volume":"14","author":"Leonardi C","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0147-0"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0258-0"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16233"},{"key":"e_1_2_6_13_1","first-page":"845","article-title":"A prospective, open\u2010label study evaluating adjunctive calcipotriene 0.005%\/betamethasone dipropionate 0.064% foam in psoriasis patients with inadequate response to biologic therapy","volume":"17","author":"Bagel J","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_14_1","first-page":"801","article-title":"Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study","volume":"16","author":"Strober B","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1273469"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12453"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04596.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000458415"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T20:22:23Z","timestamp":1693599743000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":17,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/jdv.17028"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17028","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}